Successful Treatment of Encapsulating Peritoneal Sclerosis by Hemodialysis and Peritoneal Lavage Using Dialysate Containing Dissolved Hydrogen

Terawaki, Hiroyuki; Nakano, Hirofumi; Zhu, Wan Jun; Nakayama, Masaaki

doi:10.3747/pdi.2013.00255

Cited by 8 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have also suggested that peritoneal dialysate containing hydrogen could preserve MCs, indicating hydrogen may suppress peritoneal fibrosis . A clinical case report has indicated that hydrogen‐dissolved peritoneal dialysate could successfully treat a patient with encapsulating peritoneal sclerosis . However, the protective mechanism of hydrogen on MCs remains unexamined and needs to be further researched.…”

Section: Introductionmentioning

confidence: 99%

“…20 A clinical case report has indicated that hydrogen-dissolved peritoneal dialysate could successfully treat a patient with encapsulating peritoneal sclerosis. 21 However, the protective mechanism of hydrogen on MCs remains unexamined and needs to be further researched. Therefore, the present study explored if hydrogen has a therapeutic potential for peritoneal fibrosis through altering PTEN expression and its related pathways.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Molecular hydrogen regulates PTEN‐AKT‐mTOR signaling via ROS to alleviate peritoneal dialysis‐related peritoneal fibrosis

Chen

Liu

et al. 2020

FASEB j.

View full text Add to dashboard Cite

As a convenient, effective and economical kidney replacement therapy for end‐stage renal disease (ESRD), peritoneal dialysis is available in approximately 11% of ESRD patients worldwide. However, long‐term peritoneal dialysis treatment causes peritoneal fibrosis. In recent years, the application potential of molecular hydrogen in the biomedicine has been well recognized. Molecular hydrogen selectively scavenges cytotoxic reactive oxygen species (ROS) and acts as an antioxidant. In this experiment, a high glucose‐induced peritoneal fibrosis mouse model was successfully established by intraperitoneal injection of high glucose peritoneal dialysate, and peritoneal fibrosis mice were treated with hydrogen‐rich peritoneal dialysate. In addition, in vitro studies of high glucose‐induced peritoneal fibrosis were performed using MeT‐5A cells. In vitro and in vivo experiments show that molecular hydrogen could inhibit peritoneal fibrosis progress induced by high glucose effectively. Furthermore, it has been found that molecular hydrogen alleviate fibrosis by eliminating intracellular ROS and inhibiting the activation of the PTEN/AKT/mTOR pathway. The present data proposes that molecular hydrogen exerts the capacity of anti‐peritoneal fibrosis through the ROS/PTEN/AKT/mTOR pathway. Therefore, molecule hydrogen is a potential, safe, and effective treatment agent, with peritoneal protective property and great clinical significance.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Molecular hydrogen regulates PTEN‐AKT‐mTOR signaling via ROS to alleviate peritoneal dialysis‐related peritoneal fibrosis

Chen

Liu

et al. 2020

FASEB j.

View full text Add to dashboard Cite

show abstract

“…H 2 dissolved in water, given orally or by intraperitoneal administration, can suppress oxidative or inflammatory injury in various types of animal models, by playing a role as modulator of the expression of various molecules, such as MAPK, MEK-1, NFκB, and caspase-3 and 12, and by upregulating Nrf-2, which could prevent oxidative injury and apoptosis [ 21 ]. Thus, addition of H 2 to PD solutions could represent a unique clinical approach to protecting the mesothelial cells and peritoneal tissue of these patients [ 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Dissolved molecular hydrogen (H2) in Peritoneal Dialysis (PD) solutions preserves mesothelial cells and peritoneal membrane integrity

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundPeritoneal dialysis (PD) is used as renal replacement therapy in patients with end-stage kidney disease. However, peritoneal membrane failure remains problematic and constitutes a critical cause of PD discontinuation. Recent studies have revealed the unique biological action of molecular hydrogen (H2) as an anti-oxidant, which ameliorates tissue injury. In the present study, we aimed to examine the effects of H2 on the peritoneal membrane of experimental PD rats.MethodEight-week-old male Sprague-Dawley rats were divided into the following groups (n = 8–11 each) receiving different test solutions: control group (no treatment), PD group (commercially available lactate-based neutral 2.5% glucose PD solution), and H2PD group (PD solution with dissolved H2 at 400 ppb). Furthermore, the influence of iron (FeCl3: 5 μM: inducer of oxidative cellular injury) in the respective PD solutions was also examined (Fe-PD and Fe-H2PD groups). The H2PD solution was manufactured by bathing a PD bag in H2-oversaturated water created by electrolysis of the water. Twenty mL of the test solutions were intraperitoneally injected once a day for 10 days. Parietal peritoneum samples and cells collected from the peritoneal surface following treatment with trypsin were subjected to analysis.ResultsIn the PD group as compared to controls, a mild but significant sub-mesothelial thickening was observed, with increase in the number of cells in the peritoneal surface tissue that were positive for apoptosis, proliferation and vimentin, as seen by immunostaining. There were significantly fewer of such changes in the H2PD group, in which there was a dominant presence of M2 (CD163+) macrophages in the peritoneum. The Fe-PD group showed a significant loss of mesothelial cells with sub-mesothelial thickening, these changes being ameliorated in the Fe-H2PD group.ConclusionH2-dissolved PD solutions could preserve mesothelial cells and peritoneal membrane integrity in PD rats. Clinical application of H2 in PD could be a novel strategy for protection of peritoneal tissue during PD treatment.

show abstract

“…of this system have been accumulating. We and our collaborators have so far observed various clinical benefits in patients receiving this therapy [29,85]. H 2 -enriched HD solution corrected intra-and inter-dialytic high blood pressure (Fig.…”

Section: Manufacture and Delivery Of H 2 Dialysate Using Water Electrmentioning

confidence: 98%

The hydrogen molecule as antioxidant therapy: clinical application in hemodialysis and perspectives

2016

Self Cite

View full text Add to dashboard Cite

Increased oxidative stress and pro-inflammatory conditions, commonly present in chronic dialysis patients, are thought to be enhanced during hemodialysis (HD) and to be associated with the excess morbidity and mortality seen in these patients. The hydrogen molecule (H 2 ) has a unique biological capacity to act as an antioxidative and anti-inflammatory substance. In light of accumulating evidence from animal studies showing protective effects against organ damage during ischemia and inflammation, development of H 2 treatments for HD patients has become a challenging clinical goal. An HD system utilizing a water electrolysis technique that renders large amounts of H 2 -enriched water has been developed. During HD with an H 2 -enriched solution (approximately 50 ppb H 2 ), markers of increased oxidative stress (such as interleukin-6, myeloperoxidase, methemoglobin, increased lymphocyte apoptosis, and high blood pressure) are suppressed. These findings indicate that the use of an H 2 -enriched solution may prove to be a novel approach to ameliorate dialysis-related complications. This manuscript reviews the recent progress in H 2 research and the use of H 2 in HD patients, including a description of a water electrolysis technique that delivers large amounts of H 2 -enriched water for use in clinical settings.

show abstract

Successful Treatment of Encapsulating Peritoneal Sclerosis by Hemodialysis and Peritoneal Lavage Using Dialysate Containing Dissolved Hydrogen

Cited by 8 publications

References 32 publications

Molecular hydrogen regulates PTEN‐AKT‐mTOR signaling via ROS to alleviate peritoneal dialysis‐related peritoneal fibrosis

Molecular hydrogen regulates PTEN‐AKT‐mTOR signaling via ROS to alleviate peritoneal dialysis‐related peritoneal fibrosis

Dissolved molecular hydrogen (H2) in Peritoneal Dialysis (PD) solutions preserves mesothelial cells and peritoneal membrane integrity

The hydrogen molecule as antioxidant therapy: clinical application in hemodialysis and perspectives

Contact Info

Product

Resources

About